Company intelligence / Profile preview

Theravance Respiratory Company

South San Francisco, California, United States

Ownership: Private
Development stage: Other

Overview

Theravance Respiratory Company LLC was formed to collect and distribute royalty interests in TRELEGY ELLIPTA. The product is highly successful commercially for COPD and asthma, and in 2023 Royalty Pharma acquired the economic interest in the entity from Theravance and Innoviva.

Therapeutic areas: Pulmonology
Modalities: Small molecule
Industry: Investors

Partnerships

GSK (commercialization partner for TRELEGY ELLIPTA)

Beyond the preview

Go deeper on Theravance Respiratory Company.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Theravance Respiratory Company.

Explore the full profile